Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Ina Lim

Internal Medicine Silver Spring, MD Medical Doctor

NPI 1073891768 CMS profile 707667

11886 Healing Way Ste 401, Silver Spring, MD 20904

Open in the dashboard

General payments

$4,485

228 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ina Lim of Silver Spring, MD is reported in the CMS Open Payments database as having received $4,485 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,075 49
2024 General $924 41
2023 General $618 31
2022 General $803 40
2021 General $241 12
2020 General $824 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ina Lim
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ina Lim were reported at $1,075. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ina Lim Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $824 $119 $33–$402 $114
2021 $241 $135 $37–$521 $132
2022 $803 $141 $42–$496 $149
2023 $618 $149 $45–$519 $160
2024 $924 $154 $47–$537 $164
2025 $1,075 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Novo Nordisk Inc $823 54 payments
  2. Lilly USA, LLC $820 42 payments
  3. AstraZeneca Pharmaceuticals LP $664 30 payments
  4. Amgen Inc. $429 23 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $234 10 payments
  6. Pfizer Inc. $232 12 payments
  7. Inspire Medical Systems, Inc. $164 2 payments
  8. GlaxoSmithKline, LLC. $148 8 payments
  9. Exact Sciences Corporation $124 6 payments
  10. Corcept Therapeutics $118 6 payments
  11. Other $732 35 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,485 228 payments
Products named General payments · program years 2020–2025
  1. Ozempic $664 42 payments
  2. RYBELSUS $660 42 payments
  3. MOUNJARO $446 21 payments
  4. EVENITY $270 14 payments
  5. ZEPBOUND $269 10 payments
  6. JARDIANCE $268 15 payments
  7. TRULICITY $252 15 payments
  8. Prolia $212 11 payments
  9. FARXIGA $182 9 payments
  10. AIRSUPRA $171 7 payments
  11. Other $3,157 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

5,216

Median for Family Practice: 1,826

Drug cost

$576,427

Median for Family Practice: $120,094

Branded share of claims

19.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 49 $125,743
Jardiance Empagliflozin Brand 55 $88,143
Eliquis Apixaban Brand 59 $82,125
Trulicity Dulaglutide Brand 25 $45,283
Rybelsus Semaglutide Brand 11 $24,026
Farxiga Dapagliflozin Propanediol Brand 20 $21,607
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 13 $21,580
Tradjenta Linagliptin Brand 15 $21,122
Xarelto Rivaroxaban Brand 12 $17,781
Januvia Sitagliptin Phosphate Brand 14 $13,635

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$78,417

Of which drugs: $27,969

Medicare patients

282

Average age 75

Services billed

1,762

187 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Diabetes 37%
Ischemic heart disease 20%
Chronic kidney disease 17%
Osteoporosis 17%
Atrial fibrillation 14%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 12 1,020 $20,316
Pcv20 vaccine im 90677 Office 18 18 $4,910
Vaccine for influenza for injection into muscle 90653 Office 29 29 $2,373

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $83
  • Lilly USA, LLC $20
$104 55 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $97
$97 — —
MAVYRET
  • AbbVie, Inc. $51
$51 — —
RYBELSUS
  • Novo Nordisk Inc $49
$49 11 —
Ozempic
  • Novo Nordisk Inc $49
$49 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record